Omeros Corporation
Moat Score — Omeros Corporation
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | YARTEMLEA (narsoplimab) holds orphan-drug exclusivity and patent protection as the first and only FDA-approved therapy for TA-TMA, built on Omeros's proprietary, two-decade-old MASP-2/MASP-3 complement-targeting antibody platform. Novo Nordisk's willingness to pay roughly $2 billion for the related zaltenibart asset is independent validation of that platform's IP value, though the company's commercial portfolio still rests on a single approved molecule. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Omeros has no low-cost manufacturing or scale advantage; as a newly commercial specialty biologic maker it prices YARTEMLEA as a premium orphan therapy and carries R&D and launch costs typical of a small biopharma, not a cost leader's structure. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | With no approved on-label competitor in TA-TMA, Omeros can price YARTEMLEA as a true first-in-class orphan therapy in the U.S., where early sales ($38.4 million in H1 2026) reflect that leverage. Pricing power is currently confined to the U.S., however, since the CHMP's negative opinion has stalled EU market access. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | YARTEMLEA and zaltenibart are standard biologic therapeutics with no network dynamic — clinical value does not increase as more patients, hospitals, or payors adopt the drug, unlike a platform or marketplace business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a transplant center adopts YARTEMLEA as its TA-TMA standard of care, practical switching costs exist in the form of established dosing protocols and physician familiarity, but TA-TMA treatment is episodic (tied to a single transplant event) rather than a chronic, recurring relationship, limiting how durable that inertia is. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | TA-TMA is a narrow, severe complication affecting only a subset of roughly 20,000-plus annual U.S. allogeneic transplants, concentrated at about 80 transplant centers — a market small enough that it may not economically support a second dedicated competitor once YARTEMLEA is entrenched, even though it is far too small to be a scale moat on Omeros's broader balance sheet. |